Wave Life Sciences Ltd. (WVE) NASDAQ

6.52

-0.02(-0.31%)

Updated at May 09 10:45AM

Currency In USD

Wave Life Sciences Ltd.

Address

Marina One East Tower

Singapore, 018936

Singapore

Phone

65 6236 3388

Sector

Healthcare

Industry

Biotechnology

Employees

287

First IPO Date

November 11, 2015

Key Executives

NameTitlePayYear Born
Dr. Paul B. Bolno M.B.A., M.D.President, Chief Executive Officer & Director1.21M1974
Dr. Gregory L. Verdine Ph.D.Founder & Director47,5001959
Dr. Christopher Francis Ph.D.Senior Vice President of Corporate Development & Head of Emerging Areas696,1101978
Mr. Kyle B. Moran CFAChief Financial Officer & Principal Accounting Officer788,4671971
Dr. Chandra Vargeese Ph.D.Chief Technology Officer789,4291961
Ms. Linda Rockett J.D.Senior Vice President & General Counsel0N/A
Dr. Erik Ingelsson M.D., Ph.D.Chief Scientific Officer0N/A
Ms. Daryn LewisSenior Vice President & Head of Human Resources0N/A
Ms. Kate RauschHead of Investor Relations0N/A
Dr. Sridhar Vaddeboina Ph.D.Senior Vice President of Chemistry, Manufacturing & Controls0N/A

Description

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.